1 |
HADDOX C L, RIEDEL R F. Recent advances in the understanding and management of liposarcoma[J]. Fac Rev, 2021, 10: 1.
|
2 |
JAFARI A, REZAEI-TAVIRANI M, FARHADIHOSSEINABADI B, et al. Human amniotic mesenchymal stem cells to promote/suppress cancer: two sides of the same coin[J]. Stem Cell Res Ther, 2021, 12(1): 126.
|
3 |
CUNNINGHAM R, HANSEN C G. The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer[J]. Clin Sci, 2022, 136(3): 197-222.
|
4 |
TRAUTMANN M, CHENG Y Y, JENSEN P,et al. Requirement for YAP1 signaling in myxoid liposarcoma[J]. EMBO Mol Med, 2019, 11(5): e9889.
|
5 |
ZANCONATO F, CORDENONSI M, PICCOLO S. YAP and TAZ: a signalling hub of the tumour microenvironment[J]. Nat Rev Cancer, 2019, 19(8): 454-464.
|
6 |
ANDRZEJEWSKA A, LUKOMSKA B, JANOWSKI M. Concise review: mesenchymal stem cells: from roots to boost[J]. Stem Cells, 2019, 37(7): 855-864.
|
7 |
TU B, ZHU J, LIU S, et al. Mesenchymal stem cells promote osteosarcoma cell survival and drug resistance through activation of STAT3[J]. Oncotarget, 2016, 7(30): 48296-48308.
|
8 |
ZENG J C, CHEN S S, LI C H, et al. Mesenchymal stem/stromal cells-derived IL-6 promotes nasopharyngeal carcinoma growth and resistance to cisplatin via upregulating CD73 expression[J]. J Cancer, 2020, 11(8): 2068-2079.
|
9 |
GAO T, YU Y, CONG Q, et al. Human mesenchymal stem cells in the tumour microenvironment promote ovarian cancer progression: the role of platelet-activating factor[J]. BMC Cancer, 2018, 18(1): 999.
|
10 |
NISHIKAWA G, KAWADA K, NAKAGAWA J, et al. Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression via CCR5[J]. Cell Death Dis, 2019, 10(4): 264.
|
11 |
AL-TOUB M, ALMOHAWES M, VISHNUBALAJI R, et al. CXCR7 signaling promotes breast cancer survival in response to mesenchymal stromal stem cell-derived factors[J]. Cell Death Discov, 2019, 5: 87.
|
12 |
CHEN J, JI T, WU D, et al. Human mesenchymal stem cells promote tumor growth via MAPK pathway and metastasis by epithelial mesenchymal transition and integrin α5 in hepatocellular carcinoma[J]. Cell Death Dis, 2019, 10(6): 425.
|
13 |
WENG Z J, ZHANG B W, WU C Z, et al. Therapeutic roles of mesenchymal stem cell-derived extracellular vesicles in cancer[J]. J Hematol Oncol, 2021, 14(1): 136.
|
14 |
LIN Z J, WU Y L, XU Y T, et al. Mesenchymal stem cell-derived exosomes in cancer therapy resistance: recent advances and therapeutic potential[J]. Mol Cancer, 2022, 21(1): 179.
|
15 |
ZHANG X N, SAI B Q, WANG F, et al. Hypoxic BMSC-derived exosomal miRNAs promote metastasis of lung cancer cells via STAT3-induced EMT[J]. Mol Cancer, 2019, 18(1): 40.
|
16 |
LI H D, LI F. Exosomes from BM-MSCs increase the population of CSCs via transfer of miR-142-3p[J]. Br J Cancer, 2018, 119(6): 744-755.
|
17 |
MONTALTO F I, AMICIS F D. Cyclin D1 in cancer: a molecular connection for cell cycle control, adhesion and invasion in tumor and stroma[J]. Cells, 2020, 9(12): 2648.
|
18 |
MIZUNO T, MURAKAMI H, FUJII M, et al. YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes[J]. Oncogene, 2012, 31(49): 5117-5122.
|
19 |
LOUIS-BRENNETOT C, COINDRE J M, FERREIRA C, et al. The CDKN2A/CDKN2B/CDK4/CCND1 pathway is pivotal in well-differentiated and dedifferentiated liposarcoma oncogenesis: an analysis of 104 tumors[J]. Genes Chromosomes Cancer, 2011, 50(11): 896-907.
|
20 |
YANG P P, CHEN W C, LI X H, et al. Downregulation of cyclin D1 sensitizes cancer cells to MDM2 antagonist Nutlin-3[J]. Oncotarget, 2016, 7(22): 32652-32663.
|
21 |
HOSSEINI S, CHAMANI J, HADIPANAH M R, et al. Nano-curcumin’s suppression of breast cancer cells (MCF7) through the inhibition of cyclinD1 expression[J]. Breast Cancer, 2019, 11: 137-142.
|
22 |
GAO F, LI M, ZHOU L, et al. Xanthohumol targets the ERK1/2-Fra1 signaling axis to reduce cyclin D1 expression and inhibit non-small cell lung cancer[J]. Oncol Rep, 2020, 44(4): 1365-1374.
|
23 |
MENG H, LI J, SUN H P, et al. The transcription factor ATF2 promotes gastric cancer progression by activating the METTL3/cyclin D1 pathway[J]. Drug Dev Res, 2023, 84(6): 1325-1334.
|
24 |
MONDAL S, ADHIKARI N, BANERJEE S, et al. Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: a minireview[J]. Eur J Med Chem, 2020, 194: 112260.
|
25 |
WANG W M, LI D, XIANG L L, et al. TIMP-2 inhibits metastasis and predicts prognosis of colorectal cancer via regulating MMP-9[J]. Cell Adh Migr, 2019, 13(1): 273-284.
|
26 |
KARMAKAR D, MAITY J, MONDAL P, et al. E2F5 promotes prostate cancer cell migration and invasion through regulation of TFPI2, MMP-2 and MMP-9[J]. Carcinogenesis, 2020, 41(12): 1767-1780.
|
27 |
LIU B Q, TIAN Y S, CHEN M Y, et al. CircUBAP2 promotes MMP9-mediated oncogenic effect via sponging miR-194-3p in hepatocellular carcinoma[J]. Front Cell Dev Biol, 2021, 9: 675043.
|
28 |
RODRIGUEZ R, TORNIN J, SUAREZ C, et al. Expression of FUS-CHOP fusion protein in immortalized/transformed human mesenchymal stem cells drives mixoid liposarcoma formation[J]. Stem Cells, 2013, 31(10): 2061-2072.
|
29 |
KIM Y J, KIM M, PARK H K, et al. Co-expression of MDM2 and CDK4 in transformed human mesenchymal stem cells causes high-grade sarcoma with a dedifferentiated liposarcoma-like morphology[J]. Lab Invest, 2019, 99(9): 1309-1320.
|
30 |
JO E B, LEE H, LEE K W, et al. Complete regression of metastatic de-differentiated liposarcoma with engineered mesenchymal stromal cells with dTRAIL and HSV-TK[J]. Am J Transl Res, 2020, 12(7): 3993-4000.
|